Abbott Laboratories (ABT) – What Are Investment Firms Thinking About This Stock?

Abbott Laboratories (NYSE:ABT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-seven analysts that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, twenty-two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $119.04.

A number of brokerages have issued reports on ABT. Citigroup decreased their price target on Abbott Laboratories from $125.00 to $122.00 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. UBS Group decreased their price target on shares of Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Leerink Partners raised shares of Abbott Laboratories from a “market perform” rating to an “outperform” rating and set a $124.00 price objective for the company in a research note on Thursday. Finally, Argus downgraded Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th.

Get Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Trading Down 0.4%

Shares of Abbott Laboratories stock opened at $104.03 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $129.85. The firm has a market cap of $180.17 billion, a PE ratio of 38.82, a P/E/G ratio of 1.83 and a beta of 0.54. The business’s fifty day moving average is $103.89 and its two-hundred day moving average is $101.69. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, meeting analysts’ consensus estimates of $1.42. The business had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.30 earnings per share. Analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, November 16th. Shareholders of record on Thursday, October 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Thursday, October 15th. Abbott Laboratories’s payout ratio is 94.03%.

Insider Buying and Selling

In other news, EVP Mary Moreland sold 3,500 shares of Abbott Laboratories stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the transaction, the executive vice president directly owned 100,791 shares of the company’s stock, valued at $11,691,756. The trade was a 3.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.46% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Abbott Laboratories

Several institutional investors have recently bought and sold shares of ABT. Foresight Capital Management Advisors Inc. purchased a new position in Abbott Laboratories in the 3rd quarter valued at about $31,000. Manning & Napier Advisors LLC purchased a new stake in shares of Abbott Laboratories during the second quarter worth about $31,000. Balance Wealth Partners LLC purchased a new stake in shares of Abbott Laboratories during the third quarter worth about $34,000. Summit Securities Group LLC lifted its stake in shares of Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock worth $37,000 after acquiring an additional 118 shares in the last quarter. Finally, DiPaolo Financial Group Inc. purchased a new stake in Abbott Laboratories during the 3rd quarter worth approximately $40,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Abbott Laboratories

Here are a few of the latest stories about ABT:

  • Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, signaling increased confidence in the company’s prospects. MedTech poised to outperform in 2027, Leerink says as Abbott upgraded
  • Positive Sentiment: Abbott began the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to help tailor valve deployment to a patient’s anatomy, potentially strengthening Abbott’s structural-heart pipeline; trial results will be needed to establish its safety and efficacy. Abbott initiates VOYAGER clinical trial
  • Positive Sentiment: A commentary highlighted Abbott’s 54 consecutive years of dividend growth and said a potential spin-off of its nutrition division could lead to a re-rating of the stock. The spin-off remains a prospective catalyst, not a confirmed outcome in the article. 3 Dividend Kings to Buy in November and Never Sell

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.

Further Reading

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.